Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

Completed · Phase 2

Conditions studied: Graft-Versus-Host Disease

In brief

This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplant.

Key facts

Study ID

NCT00201799

Run by

Ohio State University Comprehensive Cancer Center

People needed

19

Starts

2004-02-01

Expected to finish

2008-03-01

Last updated by the study team

2015-06-10

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing allogeneic HCT for the following disorders:
• Acute myelogenous leukemia
• Acute lymphoblastic leukemia
• Non-Hodgkin's lymphoma
• Hodgkin's disease
• Multiple myeloma
• Chronic lymphocytic leukemia
• Chronic myeloid leukemia in accelerated or blast crisis at time of transplant.
• Age >20 yrs

You may not qualify if…

• Patients undergoing allogeneic stem cell transplantation for chronic myelogenous leukemia and aplastic anemia are excluded.
• Pregnant or breast-feeding females.

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.